SCHEMBL62015

SCHEMBL62015

CCCCCCCCCC1=CCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
ALOX15 P16050 1/20 0.40
SCD O00767 1/20 0.36
PKM P14618 1/20 0.36
PTGS2 P35354 3/20 0.35
ESR1 P03372 2/20 0.35
ADRA2A P08913 2/20 0.35
ADORA3 P0DMS8 2/20 0.35
TACR2 P21452 2/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
KCNH2 Q12809 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
SHBG P04278 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
HSPD1 P10809 1/20 0.35
ADRB3 P13945 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9269668 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL60560 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL9214222 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL5345644 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL8948566 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL7614797 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL9205180 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL7606977 1.00 ALDH1A1 (0.40) ALDH1A1ALOX15SCDPKMPTGS2
SCHEMBL1423814 0.98 ALDH1A1 (0.41) ALDH1A1ALOX15PKMPTGS2LMNA
SCHEMBL7459531 0.94 ALDH1A1 (0.46) ALDH1A1ALOX15PKMPTGS2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS, LLC 2023-07-13 US disclosed
US-11612608-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2023-03-28 US disclosed
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2020-07-09 US disclosed
US-10610533-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2020-04-07 US disclosed
EP-3527079-A1 METHODS OF TREATING ORAL MUCOSITIS Galera Labs, LLC (US) 2019-08-21 EP disclosed
EP-2056675-B1 METHODS OF TREATING ORAL MUCOSITIS GALERA LABS LLC (US) 2019-01-09 EP disclosed
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS BIOSSIL INC. (CA) 2018-11-22 US disclosed
EP-3287464-A1 ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS Abbott Laboratories (US) 2018-02-28 EP disclosed
US-9855279-B2 Methods of treating oral mucositis GALERA LABS, LLC (US) 2018-01-02 US disclosed
EP-2859916-B1 Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy GALERA LABS LLC (US) 2017-11-29 EP disclosed
WO-1996040658-A1 PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES MONSANTO COMPANY (US) 1996-12-19 WO disclosed
WO-1996039396-A1 MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1996-12-12 WO disclosed
WO-1995028968-A1 DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES MONSANTO COMPANY (US) 1995-11-02 WO disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
WO-1994015925-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1994-07-21 WO disclosed
EP-0598753-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1994-06-01 EP disclosed
WO-1993002090-A1 MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE MONSANTO COMPANY (US) 1993-02-04 WO disclosed
EP-0524161-A1 Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide MONSANTO COMPANY (US) 1993-01-20 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333421-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO ALDH1A1 664/4885ALOX15 540/4885SCD 2533/4885
US-20200215077-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO ALDH1A1 664/4885ALOX15 540/4885SCD 2533/4885
US-20230218633-A1 METHODS OF TREATING ORAL MUCOSITIS LPO, SOD3, MPO ALDH1A1 664/4885ALOX15 540/4885SCD 2533/4885
US-10610533-B2 Methods of treating oral mucositis LPO, SOD3, MPO ALDH1A1 664/4885ALOX15 540/4885SCD 2533/4885
US-11612608-B2 Methods of treating oral mucositis LPO, SOD3, MPO ALDH1A1 664/4885ALOX15 540/4885SCD 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.